TORONTO, ONTARIO -- (April 21, 2016) - ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce the engagement of Conductive Technologies Inc. (CTI) of York, Pennsylvania to assist with biosensor development on the Company’s HemoPalm technology.
ChroMedX has previously reported on the collaboration with Polygenesis on the development of the biosensor system and associated components which are key aspects of the HemoPalm system.
“We are pleased to announce that Conductive Technologies Inc. (CTI) of York, PA have now joined this collaborative program. Our biosensor development program with Polygenesis Corp. has progressed as expected with basic electronics being established and testing of biosensors currently taking place. CTI supplied the initial gold electrode array deposited on polymeric substrate to ChroMedX and is now fully engaged developing production methods for the manufacture of the ion-specific electrodes.”, said Dr. Wayne Maddever, President & CEO, ChroMedX Corp.
A critical component in the production method is CTI’s equipment and expertise for automatic deposition of minute volumes of liquid on tiny portions of the gold electrodes which subsequently solidify to become ion-specific membranes. Dr. Matthew Musho, President of Conductive Technologies Inc., said. “We are pleased to be a part of this exciting development programme with ChroMedX. CTI continually looks for new applications for its biosensor technology and the HemoPalm system holds great promise as a diagnostic tool.”
About Conductive Technologies Inc. Conductive Technologies was founded in 1948 and is a leading global developer and manufacturer of electrochemical sensors and printed electronics. The company operations in York, PA include over 100 employees in over 100,000 square feet of operating space. CTI is EN ISO 13485, ISO 13485 & ISO 9001 certified
About ChroMedX Corp. ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.
